Jesper Dahl

Jesper Dahl

Auto-generated profile, based on publicly available information

Jesper Dahl

Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
JDJesper Dahl
Jesper Dahl
ERErle Refsum
Erle Refsum
MAMaria Therese Ahlen
Maria Therese Ahlen
TETorstein Egeland
Torstein Egeland
TJTore Jensen
Tore Jensen
HTHeidi Tiller
Heidi Tiller

23 December 2023 in Vaccine
Verified
Journal Article
Open access
ESElina Seppälä
Elina Seppälä
JDJesper Dahl
Jesper Dahl
LVLamprini Veneti
Lamprini Veneti
KRKjersti Margrethe Rydland
Kjersti Margrethe Rydland
BKBirgitte Klüwer
Birgitte Klüwer
HMHinta Meijerink
Hinta Meijerink
Co-circulation of SARS-CoV-2 and influenza virus can lead to double epidemics and increased pressure on health systems. To evaluate the effect of both vaccines, we estimated the adjusted vaccine effectiveness (aVE) of influenza and Covid-19 vaccines against related severe disease in the elderly population in Norway during the 2022/2023 season. In this population-based cohort study, we included data from the Emergency preparedness register for Covid-19 (Beredt C19) on all individuals ≥ 65 years living in Norway between 3 October 2022 and 20 June 2023. Using Cox-proportional hazard models, we estimated aVE of both influenza and Covid-19 vaccines (bivalent BA.1 and BA.4-5) against associated hospitalisation and death. Vaccine status was included as a time-varying covariate and all models were adjusted for potential confounders, including the other vaccine. We identified 2,437 influenza-associated hospitalisations and 178 deaths, alongside 5,824 Covid-19-associated hospitalisations and 621 deaths. The aVE was highest in the first three months after receiving either vaccine. Against influenza-associated hospitalisation the aVE was 34 % (26 %-42 %) among 65-79-year-olds and 40 % (30 %-48 %) among ≥ 80-year-olds, and 6.6 % (-64 %-47 %) and 37 % (0.5 %-61 %) against influenza-associated death, respectively. The aVE against Covid-19-associated hospitalisation was 65 % (61 %-69 %) among 65-79-year-olds and 55 % (49 %-60 %) among ≥ 80-year-olds (compared to having received the vaccine ≥ 180 days ago). Similarly, the aVE against Covid-19-associated death was 68 % (48 %-80 %) and 78 % (65 %-86 %), respectively. For Covid-19 we show a reduction in aVE with time since dose. Covid-19 and influenza vaccines reduced the risk of severe disease in the same high-risk population. Ensuring high uptake of both vaccines could thus limit the overall health care burden.

1 February 2016 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
JDJ. Dahl
J. Dahl
AHA. Husebekk
A. Husebekk
GAGanesh Acharya
Ganesh Acharya
KFK. Flo
K. Flo
TST.B. Stuge
T.B. Stuge
HTH. Tiller
H. Tiller

14 February 2025 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
ESElina Seppälä
Elina Seppälä
HBHåkon Bøås
Håkon Bøås
JDJesper Dahl
Jesper Dahl
JSJeanette Stålcrantz
Jeanette Stålcrantz
MSMelanie Stecher
Melanie Stecher
TPTrine Hessevik Paulsen
Trine Hessevik Paulsen
Background: In 2021, the Norwegian Institute of Public Health established temporary registry‐based surveillance of severe acute respiratory infections (SARI). We aimed to describe the surveillance system and evaluate selected attributes to inform the establishment of a permanent SARI surveillance system.Methods: SARI cases were defined using ICD‐10 discharge codes from national health and administrative registries, including codes for acute upper or lower respiratory infection (URI and LRI), COVID‐19, acute respiratory distress syndrome, pertussis or otitis media. Data from polymerase chain reaction (PCR) analyses were available for 10 respiratory pathogens including SARS‐CoV‐2, influenza virus and respiratory syncytial virus (RSV). We included data from 28 September 2020 to 31 March 2024 and calculated the following parameters: the proportion of cases tested for SARS‐CoV‐2, influenza virus and/or RSV; time between admission and registration of a SARI‐related ICD‐10 code; and proportion of cases with URI, LRI and COVID‐19.Results: We identified 214,730 SARI cases, of whom 82%, 73% and 53% were tested for SARS‐CoV‐2, influenza virus and RSV. Case peaks were predominantly driven by one or a combination of these pathogens. Median time between admission and a registered SARI diagnostic code was 5 (lower–upper quartile 3–10) days. Nowcasting and alternative case definitions for SARI with COVID‐19, influenza and RSV improved the timeliness. The ICD‐10 codes for LRIs and COVID‐19 captured only ~55% of the cases in the age group of 0–29 years compared to the routine case definition, where URIs were included.Conclusions: Registry‐based SARI surveillance provides timely data for handling epidemics of respiratory infections in Norway. We recommend establishing a permanent SARI surveillance system.

1 January 2026 in BMJ Public Health
Verified
Journal Article
Open access
JDJesper Dahl
Jesper Dahl
GTGerman Tapia
German Tapia
HBHåkon Bøås
Håkon Bøås
IBInger Johanne Landsjøåsen Bakken
Inger Johanne Landsjøåsen Bakken
HGHanne Løvdal Gulseth
Hanne Løvdal Gulseth
Introduction: Most countries worldwide have experienced excess mortality that coincides temporally with the COVID-19 mass vaccination campaigns. This has led to speculation on the potential long-term effects of the vaccines on mortality risk. Methods: The study was designed as a retrospective cohort study and included all individuals aged ≥18 years living in Norway during 1 January 2021 through 31 December 2023. Individuals were categorised as either unvaccinated (received no doses), partially vaccinated (received one or two doses) or fully vaccinated (received three or more doses) from the date of vaccination and onwards. Age-stratified Poisson models were used to estimate incidence rate ratios (IRRs) of death (all causes) between vaccination groups, adjusting for sex, calendar time, county of residence and risk group status (nursing home resident or pre-existing condition with increased risk of severe COVID-19). Results: The study included 4 645 910 individuals (49.8% women) with 132 963 deaths during follow-up. There was a higher proportion of individuals that were part of a risk group among fully vaccinated individuals compared with unvaccinated individuals in all age groups and a lower unadjusted rate of death: 51.5 versus 73.6 per 100 000 person years (py) among individuals aged 18–44 years, 295.1 versus 405.3 per 100 000 py among 45–64 years and 3620.2 versus 4783.8 per 100 000 py among 65 years or older. The adjusted IRR of death for the same age groups was 0.42 (95% CI 0.38 to 0.47), 0.39 (95% CI 0.37 to 0.41) and 0.42 (95% CI 0.41 to 0.43), respectively. The differences in the rate of death between vaccination groups were larger among men and peaked during 2022. Conclusion: Vaccinated individuals had a lower all-cause mortality rate than unvaccinated individuals during 2021–2023. This difference was larger among men and most prominent following the removal of COVID-19 control measures in 2022 but persisted throughout the study period.

4 March 2025 in European Journal of Neurology
Verified
Journal Article
Open access
AVAnders Myhre Vaage
Anders Myhre Vaage
THTrygve Holmøy
Trygve Holmøy
JDJesper Dahl
Jesper Dahl
HSHein Stigum
Hein Stigum
HMHaakon E. Meyer
Haakon E. Meyer
ONOla Nakken
Ola Nakken
Background: Dyslipidemia is common in amyotrophic lateral sclerosis (ALS). Statin use has been associated with both favorable and poor prognoses. We assessed whether statin use affects ALS survival.Methods: We linked four Norwegian health surveys (1972–2003) with mandatory national registries to obtain information on premorbid health, ALS diagnosis, and death. Using the Norwegian Prescribed Drug Registry, we identified participants who had dispensed statins pre‐ and post‐diagnosis. We first compared pre‐diagnosis statin discontinuation rates between ALS patients and matched controls. Flexible parametric models were then fitted to estimate the relationship between statin use and survival time in ALS, using restricted mean survival time and hazard ratio (HR) as effect measures.Results: A total of 524 patients (43% female) with ALS were included. Mean time from ALS diagnosis to death or end of study was 2.0 (SD 2.1) years. A substantial proportion of statin users (21%) discontinued statins during the year leading up to diagnosis. This group was characterized by poorer ALS prognosis compared to those adhering to statins and were included as statin users in our analysis. After adjusting for sex, age, birth year, riluzole use and premorbid smoking status, body mass index, and total cholesterol levels, statin use was not associated with ALS survival. The estimated mean survival difference comparing statin users to non‐users was 0.74 (95% CI −5.98 to 7.47) months, corresponding to a HR of 0.97 (95% CI 0.77–1.23).Conclusion: Statin use was not associated with ALS survival, suggesting that statins should not routinely be discontinued in ALS.